Figure 4.
E2 involvement in the developmental increase in kisspeptin expression in the RP3V. A–D, Representative coronal sections through the rPVpo of P30 mice showing kisspeptin immunoreactivity in sham (A), P15 OVX plus vehicle capsule (B), P15 OVX plus E2 capsule from P15–30 (C), and P15 OVX plus E2 capsule from P22–30 (D) animals. E, Quantitative analysis of kisspeptin immunoreactivity in the AVPV, rPVpo, and cPVpo given as the mean (+sem) number of cell bodies detected per section in sham, P15 OVX, and P15 OVX plus E2 capsule from P15–30-treated mice. F, Same data from the experiment in which P15 OVX mice were given the E2 capsule for only the last 7 d (P22–30). ***, P < 0.001 compared with respective sham and E2-treated group.